<DOC>
	<DOCNO>NCT02862574</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy andecaliximab ( GS-5745 ) versus placebo add-on therapy tumor necrosis factor ( TNF ) inhibitor methotrexate adult moderate severe rheumatoid arthritis ( RA ) .</brief_summary>
	<brief_title>Andecaliximab Add-On Therapy Tumor Necrosis Factor Inhibitor Methotrexate Regimen Adults With Moderately Severely Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Key Diagnosis RA ( accord 2010 American College Rheumatology European League Against Rheumatism ( ACR/EULAR ) classification criterion ) confirm screen Must take oral parenteral methotrexate ( MTX ) dose 7.5 25 mg/week continuously least 12 week tolerate medication , least 6 week stable dose ( defined change prescription ) prior first dose study drug Individuals MTX may also concurrent chloroquine hydroxychloroquine stable dose ( defined change prescription ) least 4 week prior Baseline ; , plan continue medication duration study Must inadequate response ≥ 12 week ongoing treatment approve , stable subcutaneous ( SC ) formulation TNF inhibitor ( adalimumab , certolizumab pegol , etanercept , golimumab ) , market SC biosimilar TNF inhibitor least 6 week stable dose ( defined change prescription ) , define : must DAS28 ( CRP ) &gt; 3.2 screening AND must ≥ 3 swollen ≥ 3 tender joint ( use DAS28 joint count ) screen baseline ( need joint ) Nonsteroidal antiinflammatory drug ( NSAIDs ) and/or oral corticosteroid ( ≤ 10 mg prednisone/day equivalent ) stable dose ( defined change prescription ) ≥ 4 week prior baseline allow throughout blinded period study . PRN NSAID indication RA also allow . ( PRN mean `` pro nata '' necessary ) Tuberculosis ( TB ) Screening : Must meet either a. b. : 1 . A negative history TB infection negative QuantiFERON® TBGold InTube test chest xray result . ( QuantiFERON® test inconclusive result may repeat one time . If repeat result also inconclusive , individual exclude study . OR , 2 . Individuals history latent TB treat full course prophylaxis per local guideline allow per investigator judgment . It responsibility investigator verify adequacy previous treatment provide appropriate documentation . In case , QuantiFERON® test need obtain . In addition , case must approve medical monitor prior enrollment . . ( Any new diagnosis latent TB prior untreated /partially treat latent TB NOT allow ( ie , individual require prophylactic therapy TB study ) . Any prior history active TB [ regardless treatment ] exclusionary ) . A negative chest xray ( view per local guideline ) active TB lung disease screening ; chest xray within 90 day screen films report available investigator review Key Current treatment disease modify antirheumatic drug ( DMARD ) MTX , chloroquine hydroxychloroquine , OR current treatment immune modulating/suppressive nonbiologic biologic medication describe study protocol Intraarticular corticosteroid injection joint within 4 week baseline Any infection require oral antimicrobial therapy within 2 week prior baseline . Current inflammatory joint disease , RA , gout , reactive arthritis , psoriatic arthritis , seronegative spondylarthritis , Lyme disease , OR current autoimmune disease : systemic lupus erythematosus ( SLE ) , inflammatory bowel disease , fibromyalgia , polymyalgia rheumatica , scleroderma , inflammatory myopathy , mixed connective tissue disease , overlap syndrome would interfere evaluation RA require protocol prohibit medication ( individual Sjogren 's syndrome control thyroiditis define investigator exclude ) Active systemic involvement secondary RA vasculitis Felty 's syndrome History follow within 12 month baseline : infection require parenteral antibiotic hospitalization , lifethreatening infection , sepsis The result follow laboratory test perform central laboratory screen meet criterion : Hemoglobin &lt; 8.0 g/dL ( International System Units ( SI ) : &lt; 80 g/L ) ; White blood cell &lt; 3.0 x 10^3 cells/mm^3 ( SI : &lt; 3.0 x 10^9 cells/L ) ; Neutrophils &lt; 1.5 x 10^3 cells/mm^3 ( SI : &lt; 1.5 x 10^9 cells/L ) ; Lymphocytes &lt; 0.5 x 10^3 cells/mm^3 ( SI : &lt; 0.5 x 10^9 cells/L ) ; Platelets &lt; 100 x 10^3 cells/mm^3 ( SI : &lt; 100 x 10^9 cells/L ) ; Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≥ 2 x upper limit normal ( ULN ) ; Total bilirubin level ≥ 2 x ULN unless individual diagnose Gilbert 's disease clearly document ; Estimated glomerular filtration rate &lt; 40 mL/min/1.73 m^2 base Modification Diet Renal Disease ( MDRD ) formula . Positive HIV serology screen Evidence active Hepatitis B Virus ( HBV ) infection Evidence active Hepatitis C Virus ( HCV ) infection Any uncontrolled clinically significant laboratory abnormality would affect interpretation study data individual 's participation study . Malignancy history malignancy lymphoproliferative disorder within 10 year screen following exception : Carcinoma situ cervix successfully treat Adequately treat basal squamous cell cancer successfully treat NOTE : Other protocol define Inclusion/ Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Tumor Necrosis Factor Inhibitor</keyword>
	<keyword>TNF-IR</keyword>
	<keyword>Methotrexate</keyword>
</DOC>